Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006). (i) & (iii) |
3. | Name of person discharging managerial responsibilities/director SAID DARWAZAH | 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person N/A |
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1 3 ABOVE | 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares ORDINARY SHARES OF 10P EACH |
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED | 8. | State the nature of the transaction PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired 150,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.06% |
11. | Number of shares, debentures or financial instruments relating to shares disposed N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) N/A |
13. | Price per share or value of transaction £22.00p | 14. | Date and place of transaction 24 JUNE 2016, LONDON |
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 13,313,161 (5.56%) COMPRISING: DIRECTLY, INCLUDING CONNECTED PERSONS: 745,383 (0.31%) INDIRECTLY THROUGH DARHOLD LIMITED: 12,567,778 (5.25%) | 16. | Date issuer informed of transaction 24 JUNE 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant N/A | 18. | Period during which or date on which exercisable N/A |
19. | Total amount paid (if any) for grant of the option N/A | 20. | Description of shares or debentures involved (class and number) N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise N/A | 22. | Total number of shares or debentures over which options held following notification N/A |
23. | Any additional information N/A | 24. | Name of contact and telephone number for queries PETER SPEIRS 0207 399 2772 |
Name of authorised official of issuer responsible for making notification Peter Speirs, Company Secretary Date of notification 27 June 2016 |
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006). (i) & (iii) |
3. | Name of person discharging managerial responsibilities/director MAZEN DARWAZAH | 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person N/A |
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1 3 ABOVE | 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares ORDINARY SHARES OF 10P EACH |
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED | 8. | State the nature of the transaction PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired 150,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.06% |
11. | Number of shares, debentures or financial instruments relating to shares disposed N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) N/A |
13. | Price per share or value of transaction £22.00p | 14. | Date and place of transaction 24 JUNE 2016, LONDON |
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 7,279,931 (3.04%) COMPRISING: DIRECTLY: 952,965 (0.40%) INDIRECTLY THROUGH DARHOLD LIMITED: 6,326,966 (2.64%) | 16. | Date issuer informed of transaction 24 JUNE 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant N/A | 18. | Period during which or date on which exercisable N/A |
19. | Total amount paid (if any) for grant of the option N/A | 20. | Description of shares or debentures involved (class and number) N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise N/A | 22. | Total number of shares or debentures over which options held following notification N/A |
23. | Any additional information N/A | 24. | Name of contact and telephone number for queries PETER SPEIRS 0207 399 2772 |
Name of authorised official of issuer responsible for making notification Peter Speirs, Company Secretary Date of notification 27 June 2016 |
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006). (i) & (iii) |
3. | Name of person discharging managerial responsibilities/director MOHAMMED 'ALI' AL-HUSRY | 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person N/A |
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1 3 ABOVE | 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares ORDINARY SHARES OF 10P EACH |
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED | 8. | State the nature of the transaction PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired 150,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.06% |
11. | Number of shares, debentures or financial instruments relating to shares disposed N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) N/A |
13. | Price per share or value of transaction £22.00p | 14. | Date and place of transaction 24 JUNE 2016, LONDON |
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 5,814,166 (2.43%) UNDER DYKB LIMITED COMPRISING: DIRECTLY: 1,162,811 (0.49%) INDIRECTLY THROUGH DARHOLD LIMITED: 4,651,355 (1.94%) | 16. | Date issuer informed of transaction 24 JUNE 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant N/A | 18. | Period during which or date on which exercisable N/A |
19. | Total amount paid (if any) for grant of the option N/A | 20. | Description of shares or debentures involved (class and number) N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise N/A | 22. | Total number of shares or debentures over which options held following notification N/A |
23. | Any additional information N/A | 24. | Name of contact and telephone number for queries PETER SPEIRS 0207 399 2772 |
Name of authorised official of issuer responsible for making notification Peter Speirs, Company Secretary Date of notification 27 June 2016 |
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Hikma Pharmaceuticals plc published this content on 27 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 June 2016 06:13:04 UTC.
Original documenthttp://otp.investis.com/clients/uk/hikma/rns/regulatory-story.aspx?cid=167&newsid=744681
Public permalinkhttp://www.publicnow.com/view/466DF25144C960431181F71501CB9C031A1E36FC